Debut Plus

₹1,824.5

▲ +139.98 +8.31%

As of 22 Oct 2026 · delayed

NSE Listed · Healthcare

Evonile Pharma Limited (NOVARTIND)

Volume: 55,38652W Range:₹672.25₹2,588.8
NSE BSE www.novartis.com/in-en AI Report
Key Ratios
Checked 1h ago
Market Cap₹4,420 Cr
Current Price₹1,824.5
Previous Close₹1,684.52
High / Low (52w)₹2,588.8 / ₹672.25
Volume55,386
Avg Vol (1W)—
Avg Vol (1M)—
Stock P/E45.19
Book Value₹331.34
Dividend Yield0%
ROE—
ROA—
Revenue (TTM)—
Revenue Growth—
Profit Margin—
Total Debt—
Shares Outstanding—
Face Value—
EPS (TTM)₹39.61
P/B5.4
Debt / Equity0.39
50 DMA₹1,858.21
200 DMA₹1,538.76
Day change+8.31%
Price Chart
₹1,824.5▲ 171.40% · 1Y
₹2391₹6727.9L
2026-04-15
2026-10-22

20-day avg volume: 48K shares

Pros
  • Company is almost debt-free.
Quarterly Results
MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025
Revenue₹104 Cr₹91 Cr₹86 Cr—₹88 Cr₹84 Cr
EBITDA₹44 Cr₹31 Cr₹31 Cr—₹38 Cr₹35 Cr
Net Profit₹32 Cr₹25 Cr₹16 Cr—₹28 Cr₹29 Cr
EPS13.0510.236.529.8111.19—
Profit & Loss (Annual)
MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Revenue₹354 Cr₹356 Cr₹334 Cr₹369 Cr—
EBITDA₹133 Cr₹133 Cr₹127 Cr₹123 Cr—
Net Profit₹93 Cr₹101 Cr₹85 Cr₹103 Cr—
EPS37.7440.8734.5——
Balance Sheet
MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Total Assets₹978 Cr₹948 Cr₹925 Cr₹983 Cr—
Total Liabilities₹160 Cr₹163 Cr₹180 Cr₹207 Cr—
Equity₹818 Cr₹785 Cr₹745 Cr₹776 Cr—
Total Debt₹3 Cr₹5 Cr₹7 Cr₹22 Cr—
Cash Flow
MetricMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Operating₹47 Cr₹75 Cr₹113 Cr₹45 Cr—
Investing₹18 Cr₹-3 Cr₹33 Cr₹-153 Cr—
Financing₹-64 Cr₹-64 Cr₹-121 Cr₹-30 Cr—
Free Cash Flow₹46 Cr₹75 Cr₹113 Cr₹44 Cr—
Shareholding
Promoter 58.68% Institutions 14.97% Public 26.35%
About Evonile Pharma Limited

Healthcare · Drug Manufacturers - Specialty & Generic

Evonile Pharma Limited is involved in the pharmaceutical business in India and internationally. It operates Pharma International (Commercial operations), Development (Drug development), Biomedical Research, and Operations. The company offers therapeutic products in the areas of bone and pain under the Voveran brand; transplantation immunology under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. The company was incorporated in 1947 and is based in Mumbai, India. As of July 29, 2026, Evonile Pharma Limited operates as a subsidiary of Waverise Investments Limited.

www.novartis.com/in-en ↗
Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

Log inSign up free

More stocks

Noble Polymers Ltd.NOCIL LimitedNoida Toll Bridge Company Ltd.Norben Tea & Exports Ltd.Northern Arc Capital Ltd.Nova Agritech LimitedNetwork People Services Technologies Ltd.N R Agarwal Industries Ltd.NRB BearingsNupur Recyclers LimitedN R Vandana Tex Industries Ltd.Nalwa Sons Investment Ltd.All “N” stocks →

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search